Overview

A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer

Status:
Active, not recruiting

Trial end date:
2024-02-01

Target enrollment:

Participant gender:

Summary

A Phase 2, multicenter, open-label, 2-stage study to assess the safety, tolerability, and efficacy of XERMELO in combination with first-line (1L) therapy (cisplatin [cis] plus gemcitabine [gem])

Phase:

Phase 2

Details

Lead Sponsor:

Lexicon Pharmaceuticals
TerSera Therapeutics LLC

Treatments:

Cisplatin
Gemcitabine